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ABSTRACT: The CpG dyad, an important genomic feature
in DNA methylation and transcriptional regulation, is an
attractive target for small molecules. To assess the utility of
minor groove binding oligomers for CpG recognition, we
screened a small library of hairpin pyrrole-imidazole
polyamides targeting the sequence 5′-CGCG-3′ and assessed
their sequence speciﬁcity using an unbiased next-generation
sequencing assay. Our ﬁndings indicate that hairpin polyamide
of sequence PyImβIm-γ-PyImβIm (1), previously identiﬁed as a high aﬃnity 5′-CGCG-3′ binder, favors 5′-GCGC-3′ in an
unanticipated reverse binding orientation. Replacement of one β alanine with Py to aﬀord PyImPyIm-γ-PyImβIm (3) restores the
preference for 5′-CGCG-3′ binding in a forward orientation. The minor groove binding hairpin 3 inhibits DNA
methyltransferase activity in the major groove at its target site more eﬀectively than 1, providing a molecular basis for design
of sequence-speciﬁc antagonists of CpG methylation.
■ INTRODUCTION
The role of epigenetic dysregulation in cancer has motivated
interest in DNA methylation and methods for its modulation.1,2
In mammals, DNA methylation occurs in the major groove of
DNA at the 5′ position of both cytosine residues in the
palindromic CG dyad (CpG). CpGs are rare in the genome and
70% methylated, with nearly all unmethylated CpGs clustered
in G,C-rich regions called “CpG islands”.3 Approximately 60%
of RNA Polymerase II transcribed human genes contain CpG
islands,4 and their methylation causes transcriptional repres-
sion.5 In cancer, for example, otherwise functional tumor
suppressor genes can be silenced by hypermethylation in their
associated CpG island.6 Importantly, inhibition of DNA
methylation at tumor suppressor genes has been shown to
reactivate apoptotic pathways and sensitize cancer cells to
previously ineﬀective chemotherapy.7,8
The most eﬀective demethylation agents are cytidine
analogues such as 5-aza-deoxycytidine which ﬁnd limited use
due to signiﬁcant side eﬀects.1 These cytidine analogues are
suicide inhibitors incorporated into DNA to form covalent
methyltransferase-DNA adducts.9 The methyltransferase is
sequestered and unavailable to methylate CpGs resulting in
genome-wide demethylation. DNA binding molecules, such as
the bis-intercalating natural product echinomycin,10 can disrupt
CpG methylation in vitro but have dose-limiting toxicities that
have abrogated further clinical advancement.11 While other
CpG methylation inhibitors are under investigation,12−14 none
of these agents have demonstrated the ability to inhibit DNA
methylation in a sequence-speciﬁc fashion.
Hairpin pyrrole-imidazole (Py-Im) polyamides are a class of
sequence-speciﬁc oligomers that bind in the minor groove of
DNA.15−20 Programmable sequence preference is accomplished
by side-by-side pairings of aromatic amino acids that distinguish
the edges of the four Watson−Crick base pairs.15−20 Referred
to as the pairing rules, Im/Py codes for G•C base pair, Hp/Py
codes for T•A base pairs, and Py/Py binds both T•A/A•T in
preference to G•C/C•G. Eight-ring hairpin oligomers linked
by a central aliphatic γ-aminobutyric acid unit have aﬃnities for
match sites with Ka ∼108 to 1010 M−1.16,21 These binding
energetics are comparable to natural transcription factors and,
like natural DNA binding proteins, are sensitive to diﬀerences
in the sequence-dependent microstructure of DNA. To relax
the curvature of all ring hairpins, β alanine (β) can be
substituted for Py-rings in some cases such that β/β pairs
replace Py/Py for T•A/A•T speciﬁcity, and Im/β replaces Im/
Py pairs in strategic locations while retaining speciﬁcity for
G•C base pair.22−26 Hairpin Py-Im polyamides usually bind
with the N-to-C terminus aligned in the 5′-to-3′ direction of
DNA, referred to as “forward orientation”.27 This modest
forward binding preference can be enforced by substitution of
the prochiral α position in the γ-turn, i.e., replacement of γ-
aminobutyric acid by (R)-2,4-diaminobutyric acid.28 Hairpin
architectures containing β/β pairs and β/ring pairs have been
found in some cases to prefer the N to C terminus aligned in a
3′-to-5′ direction of DNA.29 While adhering to the pairing
rules, this reverse hairpin orientation would bind a diﬀerent
DNA sequence. Recently, we used massively parallel sequenc-
ing methods in conjunction with biotin-tagged hairpins, termed
Bind-n-Seq, to scan genome-size DNA sequence space for
hairpin high aﬃnity sites.30 Although the canonical pairing rules
are remarkably predictive of polyamide DNA binding
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speciﬁcity, we identiﬁed high aﬃnity DNA binding sites in the
reverse orientation for several polyamides containing β/Im
pairs.30
Eight-ring hairpin Py-Im polyamides have been shown to
discriminate 5′-GGGG-3′, 5′-GCGC-3′, and 5′-GGCC-3′ with
appropriate arrangement of four Im/Py pairs.31 From
experience, sequences with CpG steps such as 5′-CGCG-3′
are not as readily accessed for reasons not well understood. In
an eﬀort to improve the aﬃnity of an eight-ring hairpin
polyamide for the sequence 5′-CGCG-3′, Sugiyama and co-
workers replaced two Im/Py pairs with Im/β pairs. A change
from PyImPyIm-γ-PyImPyIm (S1) to PyImβIm-γ-PyImβIm
(S2) aﬀorded a 65-fold increase in aﬃnity for 5′-CGCG-3′.32
Both hairpins conform to the pairing rules and would bind 5′-
CGCG-3′ in the forward orientation. In this study, we employ a
high-throughput sequencing assay of polyamide-DNA associa-
tion to revisit targeting the 5′-CGCG-3′ sequence. Our ﬁndings
indicate that hairpin polyamides of sequence PyImβIm-γ-
PyImβIm S2 favor 5′-GCGC-3′, a reverse binding mode. The
issue of designing a hairpin polyamide sequence that prefers 5′-
CGCG-3′ to 5′-GCGC-3′ remains to be solved. Using Bind-n-
Seq methods30 as our screen for a library of polyamide−biotin
conjugates, we ﬁnd that replacement of one β alanine with Py
to aﬀord PyImPyIm-γ-PyImβIm restores the preference for
forward binding 5′-CGCG-3′. Recent structural work has
shown that a cyclic Py-Im polyamide binding in the minor
groove causes signiﬁcant widening of the minor groove width of
DNA,33,34 and provides a mechanistic rationale for disruption
of DNA-binding proteins in the major groove. We demonstrate
the ability of our 5′-CGCG-3′ speciﬁc minor groove binding
hairpin polyamides to inhibit enzymatic CpG methylation in
the major groove of a 5′-CGCG-3′ sequence.
■ RESULTS
Sequence Based Analysis of PyImβIm-γ-PyImβIm
Speciﬁcity. The 5′-CGCG-3′ sequence is a compelling DNA
target for an 8-ring hairpin Py-Im polyamide because it is one of
the least represented 6-bp sequence patterns in the human
genome, potentially promoting greater genomic speciﬁcity.30
Minoshima and co-workers have previously targeted this
sequence and shown that polyamide S2 (Figure 1) can bind
the fully methylated sequence.32 In their study, the substitution
of two β’s for Py moieties resulted in improved aﬃnity for 5′-
CGCG-3′ over the eight-aromatic ring architecture S1 (SI
Figure S1). In light of recent Bind-n-Seq studies, however, we
wondered whether these changes may have also had the
unintended eﬀect of reducing the preference of the polyamide
for binding in the forward orientation.30 Bind-n-Seq is a high-
throughput sequencing method that allows facile identiﬁcation
of high aﬃnity binding sites of biotin-labeled Py-Im polyamides
by aﬃnity puriﬁcation followed by sequencing (Figure 2A).30
As a ﬁrst step, we synthesized an analogue of S2 and examined
polyamide−biotin conjugate 1 of sequence PyImβIm-γ-
PyImβIm (Figure 2B), which has a biotin aﬃnity tag appended
at the C-terminus of the heterocyclic oligomer. (Full structures
of all polyamides are in SI Figure S1.) Polyamide−biotin
conjugate 1 was incubated at 50 nM in a library of all possible
21 base pair DNA sequences, enriched, and sequenced to
identify polyamide-bound sequences. This data set was then
analyzed by the DREME algorithm to construct a motif logo
summarizing the highest aﬃnity sequences. A binding
preference for 5′-GCGC-3′ was revealed, suggestive of a
reverse binding mode (Table 1).
Redesign Hairpin for CGCG versus GCGC Preference.
In order to restore the preference for binding 5′-CGCG-3′ in
the forward orientation, we considered two possible points of
modiﬁcation (Figure 3A). First, we made a single modiﬁcation
to 1 at the turn unit, replacing the GABA turn to a chiral α-
amino GABA, aﬀording 2 (Figure 3B). The α-amino GABA
turn has previously been shown to restore forward orientation
and increase aﬃnity, including in β-containing polyamides.28−30
This eﬀect is thought to arise from a steric interaction with the
ﬂoor of the minor groove when the chiral α-amino GABA turn
unit is bound in the reverse orientation.23,28 Assessment of
Figure 1. Structure of Py-Im polyamide S2 previously reported to bind
methylated 5′-CGCG-3′ oligonucleotide duplex.32 Legend for ball-
and-stick notation.
Figure 2. (a) Scheme of Bind-n-Seq method.30 Polyamide−biotin
conjugate is incubated in a genome-sized library of all possible 21mers,
enriched, sequenced, and the resulting data set analyzed with motif-
ﬁnding software.30 (b) Polyamide 1 could potentially bind in the
forward orientation or the reverse orientation. The highest aﬃnity
binding sequence of 1 is the reverse orientation binding 5′-GCGC-3′.
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polyamide 2 by Bind-n-Seq found that this modiﬁcation
improved the reverse/forward ratio but was insuﬃcient to
restore a preferred forward orientation binding preference
(Table 1). To conﬁrm the high-throughput sequencing
ﬁndings, we performed a thermal DNA denaturation study, as
previous studies have shown that thermal stabilization (ΔTm)
of duplex DNA by Py-Im polyamides correlates well with
binding aﬃnity.35 Assays were performed with DNA
oligonucleotides diﬀering only in the central binding sequence
(5′-CGCG-3′ versus 5′-GCGC-3′) to directly test the binding
orientations identiﬁed by the Bind-n-Seq logos (Table 1). This
analysis substantiated a reverse orientation binding preference
for polyamide 1, with a ΔTm of 10.9 °C in the reverse direction
as compared to 3.4 °C in the forward direction. Modiﬁcation at
the turn to the α-amino GABA in polyamide 2 resulted in
increased stabilization of the forward 5′-CGCG-3′ oligomer by
4.5 °C; stabilization by polyamide 2 in the reverse 5′-GCGC-3′
orientation was diminished by 2.0 °C. This indicated an
improved forward preference for 5′-CGCG-3′. Nonetheless,
the relative magnitudes of the ΔTm support an overall modest
energetic preference for reverse orientation binding.
The inability of the α-amino GABA turn to enforce forward
orientation binding led us to investigate alternative solutions for
the molecular recognition of 5′-CGCG-3′ (Figure 3). We
posited that reverse binding is abetted by the ﬂexibility aﬀorded
by the two β units in the core binding region, as had been
similarly noted in polyamides containing a β/β pair.29 We thus
considered whether removing one β residue might reinstitute
suﬃcient rigidity in one of the polyamide strands to limit
reverse binding while retaining the speciﬁcity and aﬃnity
provided by the other β. Of the two β moieties in the core of
polyamide 1, the C-terminal β in the core binding region was
retained based on previous studies that have shown it is
necessary for high aﬃnity recognition of the 5′ C•G base
pair.24 To isolate the eﬀect of each modiﬁcation, we returned to
parent polyamide 1 and replaced the N-terminal β with a Py
while retaining the achiral GABA turn, to provide polyamide 3
(Figure 3B). The assessment of 3 by Bind-n-Seq followed by
DREME analysis generated a high af f inity motif consistent with
forward binding 5′-CGCG-3′ (Table 1). This was corroborated
by ΔTm measurements showing considerable preference for the
forward 5′-CGCG-3′ direction.
We further examined whether a hairpin polyamide designed
to target a reverse orientation sequence may productively bind
CpGs with high speciﬁcity. To test this, we expanded the library
of compounds to include polyamides 4−8, single modiﬁcations
targeting the 5′-GCGC/CGCG-3′ core (Figure 4). In contrast
to our ﬁndings with 5′-CGCG-3′ targeting polyamide 2, we
conﬁrmed that the incorporation of an α-amino GABA turn in
polyamide 6 restores forward orientation binding for the 5′-
GCGC-3′ sequence.30 This diﬀerence is striking given that the
two polyamides are composed of nearly identical amino acid
sequences. Bind-n-Seq data and Tm assays of polyamides 4, 5, 7,
and 8 together suggest that all other modiﬁcations preferen-
tially bind the reverse orientation, and 5, 7, and 8 do so with
poor speciﬁcity (Table 1). Indeed, among all variations tested
of both 5′-CGCG-3′ forward binding and 5′-GCGC-3′ reverse
Table 1. Preferred Binding Orientations of Polyamides 1−8 Were Queried with Bind-n-Seq to Generate the Highest Aﬃnity
Sequence Motifa
aPolyamide-mediated thermal stabilization (ΔTm) of 12 base pair oligonucleotides of the forward (5′-CGCG-3′) and reverse (5′-GCGC-3′)
sequences were used to validate the revealed motifs. Melting temperatures reﬂect the mean and standard deviation of quadruplicate measurements.
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binding cores, polyamide 3 displayed the highest speciﬁcity for
the 5′-CGCG-3′ sequence (Table 1).
Sequence-Speciﬁc Binding Hemi-Methylated DNA.
Next, we considered the potential for minor groove binding
hairpin Py-Im polyamides to prevent DNA methylation
undergoing DNA replication. To do so, they must be able to
bind the hemi-methylated DNA of daughter strands that have
not yet undergone maintenance methylation. DNA thermal
stabilization analysis was used to pursue evidence of the above
trends of binding orientation with hemi-methylated DNA
sequences. The sense strands of each of the 12 base pair
oligomers containing 5′-CGCG-3′ or 5′-GCGC-3′ cores were
methylated on both cytosines, whereas the antisense strands
were left unmethylated. Flanking sequences were modiﬁed to
lack self-complementarity and enforce hemi-methylated duplex
formation. Analysis of ΔTm of the hemi-methylated DNA
oligomers conﬁrmed the above magnitudes of stabilization and
trends of reverse and forward binding modes for 1, 2, and 3
(Table 2A).
Inhibition of Methyltransferase. With a speciﬁc poly-
amide capable of binding hemi-methylated DNA in hand, we
evaluated its application as a sequence-speciﬁc inhibitor of
DNA methyltransferases. The biotin enrichment tag was
deleted from the C-terminus by resynthesis to aﬀord parent
hairpins 1b and 3b. Melting temperature analyses conﬁrmed
that these molecules show comparable binding preference to
biotin conjugates 1 and 3, respectively (Table 2B). We
developed an in vitro assay to probe the methylation state of
speciﬁc sites employing the methylation-sensitive restriction
enzyme MluI to compare sequence speciﬁc eﬀects of 1b, 3b,
and AT-binding distamycin D as a control (SI Figure S2A). In
this assay, we measured the ability of these compounds to
inhibit the methylation activity of M.SssI, a robust prokaryotic
methyltransferase that operates in a processive manner like
human methyltransferases and shares structural similarities with
the catalytic core of human DNMT1.36 We employed the
methylation-sensitive enzyme MluI, which cleaves at seven 5′-
ACGCGT-3′ sites,37 to interrogate methylation of the λ-phage
DNA (48.5 kb), of which 5 bands were visualized by agarose gel
electrophoresis. Both 1b and 3b were titrated from increasing
concentrations 1 nM to 1 μM, while D was dosed 10-fold
higher from 10 nM to 10 μM. Full digestion of the DNA by
MluI indicates a lack of CpG methylation at 5′-ACGCGT-3′
restriction sites, and is demonstrated by positive control lane 2
(SI Figure S2B). In contrast, full methylation would protect
DNA from MluI digestion, as in lane 1 where no compound
was added to DNA prior to exposure to M.SssI for methylation.
Consistent with our biophysical characterization of the
compounds, polyamide 3b showed the most robust inhibition
of CpG methylation (SI Figure S2B, lanes 7−10) at 5′-
ACGCGT-3′ sites. In lane 10, full MluI digestion comparable
to positive control lane 2 was observed at 1 μM of 3b,
indicating this concentration was suﬃcient to block all
methylation at the cognate binding sites. Further, incomplete
protection was evidenced at 100 nM of 3b by additional,
partially digested bands in lane 9. In contrast, polyamide 1b
showed weak inhibition of M.SssI and was active only at the
highest concentration (SI Figure S2B, lanes 3−6). This reﬂects
its weaker aﬃnity for the 5′-CGCG-3′ forward binding
orientation, also observed by thermal duplex denaturation
analysis. Inhibition by 1b at 1 μM, however, is reduced relative
to that observed at 100 nM of 3b, consistent with the binding
preferences of the two molecules. There was no inhibition by
distamycin D at all concentrations tested, even at the highest
concentration of 10 μM, underscoring the importance of CpG
speciﬁcity of Py-Im polyamides in preventing CpG methylation.
To enable quantitation of enzyme activity inhibition, the
Figure 3. (a) Scheme of Py-Im polyamide binding in the minor groove
of DNA. (b) Single position changes made to hairpin polyamide 1 to
aﬀord 2 and 3. Positions are highlighted in yellow.
Figure 4. Panel of polyamides synthesized for assessment by Bind-n-
Seq and DNA thermal stabilization for binding the 5′-CGCG-3′
sequence. According to the pairing rules, polyamides 1−4 target 5′-
CGCG-3′ in the forward orientation and polyamides 5−8 target 5′-
CGCG-3′ in the reverse orientation. Structural modiﬁcations are
highlighted in yellow.
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substrate DNA was changed to a 7.5 kb fragment containing a
single 5′-ACGCGT-3′ site (Figure 5A).
We were encouraged by these results to consider the design
of an improved methylation antagonist at 5′-CGCG-3′. We
revisited the single modiﬁcations to 1 in polyamide 2 and 3 that
had promoted forward orientation binding. We combined the
α-amino modiﬁcation at the GABA turn that had encouraged 2
to bind in the forward orientation, albeit insuﬃciently, with the
Py substitution in the top strand, as in 3, to aﬀord 9b (Figure
5B). Analysis by thermal denaturation assays revealed that the
eﬀects of the modiﬁcations were additive, and 9b displayed
increased aﬃnity and preference for forward orientation
binding (Table 2B).
We then sought to determine IC50 values for the three
generations of 5′-CGCG-3′ methylation inhibitors: 1b, 3b, and
9b. With consideration for their DNA binding aﬃnities,
compounds 1b, 3b, and 9b were titrated from 10 nM to 33
μM, 330 pM to 10 μM, and 33 pM to 1 μM, respectively
(Figure 5C). It is worth noting that an additional SDS wash
step was necessary in this assay to remove the higher aﬃnity 9b
from the DNA before resolution by the MluI restriction
enzyme. Prior to the addition of this SDS incubation, inhibition
was maximally revealed to approximately 40%, due to
polyamide inhibition of the MluI restriction enzyme. Overnight
incubation of DNA in 2% SDS removed additional polyamide
and improved the revealed inhibition, suggesting the com-
pressed inhibitory range is an artifact of this method and the
high aﬃnity of 9b. The IC50 values of 1b, 3b, and 9b were
determined to be 2.2 μM (95% conﬁdence: 1.2−3.9 μM), 117
nM (95% conﬁdence: 65−210 nM), and 2.6 nM (95%
conﬁdence: 1.0−6.7 nM), respectively (Figure 5D). This is in
good correlation with the iterative improvement shown in the
biophysical analyses of these compounds, as well as the
previous qualitative in vitro assay. Polyamide 9b shows nearly
1000-fold improvement over 1b as a 5′-CGCG-3′ methylation
antagonist.
■ DISCUSSION
Design of Antagonists of CpG Methylation. This study
provides a basis for design of sequence-speciﬁc DNA-binding
molecules for targeted inhibition of CpG methylation. The
disparity in methyltransferase inhibition between AT-binding
distamycin D and hairpin polyamide 3b suggests that the
speciﬁc CpG-binding capability and widening of the minor
groove by bound Py-Im polyamides are critical for disrupting
DNA methylation in the major groove. At the same time,
applying the pairing rules demands caution in the design of
imidazole and β-rich polyamides as the inherent conformational
ﬂexibility of the β subunit can support unintended reverse
DNA-binding modes. While previous studies have shown an α-
amino GABA turn unit can be used to restore the forward
orientation binding preference of β-containing polyamides, we
found that 5′-CGCG-3′ binding Py-Im polyamides required an
alternative solution. Speciﬁcally, restoring the rigidity of the N-
terminal strand via substitution of its β-subunit with a Py
appears necessary to resolve the undesired reverse-binding of
these architectures.
Potential Mechanism for Inhibition of CpG Methyl-
ation. The lack of inhibition of CpG methylation by the
reverse binding 1b as compared to 3b at the interrogated 5′-
CGCG-3′ sites suggests that inhibition of the preceding M.SssI
enzyme is a sequence-speciﬁc, localized event. The M.SssI
methyltransferase, like eukaryotic methyltransferases, is a
“ﬂipase” that swings the target cytosine out of the double
helix and into its catalytic core.38 All known CpG
methyltransferases operate by this conserved mode of action.
Structural studies of mouse DNMT1, the relevant mammalian
methyltransferase for maintenance methylation, show that
enzyme residues enter the double helix from both the major
and minor grooves in an intercalative-manner around the target
CpG.39 These residues disrupt local base pairing and rotate the
substrate cytosine around the sugar−phosphate backbone and
into the catalytic core of the enzyme. A Py-Im polyamide
bound to the target DNA site likely acts as a stabilizing clamp in
the minor groove and prevents the intrusion of these residues.
The increased DNA stability disallows the conformational
Table 2. (A) Tm Study with Hemi-Methylated DNA Duplex; (B) Tm Study of Three Generations of 5′-CGCG-3′ Methylation
Inhibitors without Biotin Aﬃnity Tags
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reorganization of the CpG substrate necessary for catalysis and
results in the inhibition of methyltransferase activity.
■ CONCLUSION
In this study, we examined programmable Py-Im polyamides
targeting the 5′-CGCG-3′ sequence as a model for sequence-
speciﬁc inhibition of CpG methylation. The unbiased Bind-n-
Seq method was critical for revealing unanticipated binding
modes of the polyamides. Through deliberate, incremental
synthetic modiﬁcations, we were able to discern structure
activity relationships that guided improved design of CpG
methylation antagonists. Further work will be necessary to
understand whether this represents a more general solution for
controlling Py-Im polyamide orientation or is speciﬁc to the 5′-
CGCG-3′ sequence. This study demonstrates that high aﬃnity
minor groove binding Py-Im polyamides can inhibit major
groove CpG methylation by methyltransferase in a sequence-
speciﬁc manner. It will be the focus of future research to assess
these molecules as antagonists of CpG methylation in cells and
its utility in the desilencing of speciﬁc genes. It will be of
Figure 5. (a) Scheme of in vitro DNA methyltransferase (DNMT) inhibition assay. Generic polyamide shown in ball-and-stick notation and CpG
sites represented by red squares. DNA (7.5 kb) with a single MluI restriction site was incubated at 50 pM with inhibitor and subjected to methylation
by M.SssI. DNA was isolated for restriction digest by MluI to reveal methylation at the target site. (b) Single changes in polyamides 2 and 3 that
promote forward orientation binding were combined in designing 9b as a third generation candidate for improved methylation inhibition. (c)
Representative gel image of the polyamides 1b, 3b, and 9b in the assay described in (a), suggestive of diﬀerential inhibitory activity. Dose ranges of
compounds were adjusted in relation to their DNA binding aﬃnities. (d) IC50 values of 5′-CGCG-3′ targeting polyamides. Values are determined
from band intensities in the in vitro as assay shown in (c) and normalized against maximal methylation with no inhibitor. IC50 values were calculated
from at least three replicates and ﬁt to a four-variable, dose−response model.
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interest whether the intrinsic rarity of the CpG dinucleotide
sequence and noncovalent binding of polyamides will reduce
oﬀ-target eﬀects.
■ EXPERIMENTAL SECTION
Py-Im Polyamide Synthesis. Polyamides were synthesized by
microwave-assisted, solid-phase synthesis on PAM resin (Peptides
International) according to previously described protocols.40,41 The
polyamides were cleaved from resin with 3,3′-diamino-N-methyldi-
propylamine and puriﬁed by reverse phase HPLC. For biotin-
conjugated polyamides, the free amine at the C-terminus was allowed
to react with 2 equiv of preactivated PEG4-biotin NHS ester (Thermo
Scientiﬁc) and 4 equiv of DIEA for 1 h at 55 °C in DMF. The product
was puriﬁed by reverse phase HPLC and lyophilized. Purity and
identity of compounds were veriﬁed by analytical HPLC and matrix-
assisted laser desorption/ionization time-of-ﬂight (MALDI-TOF)
mass spectrometry.
Bind-n-Seq of Polyamide−Biotin Congugates. Sequence motif
logos of the highest aﬃnity DNA binding sites of polyamide−biotin
congugates 1−8 were determined according to previously reported
methods.30 Each Py-Im polyamide−biotin conjugate was equilibrated
at 50 nM concentration for 15 h with a uniquely barcoded library of all
possible 21mers. DNA associated with polyamide−biotin conjugates
were aﬃnity puriﬁed with streptavidin magnetic beads (M-280
Dynabeads) and eluted. Isolated DNA was ampliﬁed by touchdown
PCR and sequenced at the California Institute of Technology Millard
and Muriel Jacobs Genetics and Genomics Laboratory on an Illumina
HiSeq 2000 Genome Analyzer. The generated data set was then
distributed by barcode using scripts in the MERMADE pipeline and a
fasta ﬁle of a random 25% of sequences for each compound submitted
for DREME motif analysis.30
DNA Thermal Denaturation Assay. Unmethylated DNA
duplexes and hairpin polyamides were mixed to a ﬁnal concentration
of 2 and 3 μM, respectively, for polyamides 1−8, 1b, and 3b in 1 mL
total volume. For experiments with hemi-methylated oligonucleotides,
DNA duplexes and hairpin polyamides were mixed to a ﬁnal
concentration of 1 and 1.5 μM, respectively. An aqueous solution of
10 mM sodium cacodylate, 10 mM KCl, 10 mM MgCl2, and 5 mM
CaCl2 at pH 7.0 was used as analysis buﬀer. All oligonucleotides (100
μM solutions dissolved in 10 mM Tris-Cl, 0.1 mM EDTA, pH 8.0)
were purchased from Integrated DNA Technologies. The assay was
conducted on a Varian Cary 100 spectrophotometer equipped with a
thermocontrolled cell holder with a cell path length of 1 cm. Samples
were heated to 90 °C and cooled to a starting temperature of 25 °C
prior to heating at a rate of 0.5 °C/min to 90 °C. Denaturation proﬁles
were recorded at λ = 260 nm and melting temperatures were deﬁned
as the maximum of the ﬁrst derivative of the denaturation proﬁle.
Reported data represents the average of four measurements.
In Vitro Inhibition of CpG Methylation Assay. In PCR tubes,
serially diluted concentrations of polyamides 1b, 3b, and distamycin D
control were incubated in 96 μL of 10 pM unmethylated λ-phage
DNA (Promega) and 1× NEB2 buﬀer (New England Biolabs) in
DEPC-treated water (USB) for 12 h at 25 °C. Two additional samples
of DNA in buﬀer without compound were kept for controls. After
incubation, S-adenosyl methionine (New England Biolabs) and M.SssI
(New England Biolabs) or water was added to all samples to a ﬁnal
concentration of 320 μM and 0.25 Units, respectively, to aﬀord 100 μL
of total solution. Samples were then incubated for 3 h at 37 °C on a
Biorad MyCycler thermal cycler and heat inactivated for 15 min at 65
°C. DNA was ethanol precipitated in a centrifuge at 4 °C for 15 min
with the addition of 10 μL of 3 M NaOAc, 1 μL of glycogen, and 2.5
volumes of ethanol at −20 °C. DNA was washed once with 75%
aqueous ethanol at −20 °C and allowed to air-dry for 30 min. Samples
were dissolved in 35 μL of water and 15 μL taken for MluI restriction
enzyme digestion. Samples were prepared in PCR tubes per
manufacturer’s protocol with 1 Unit of MluI per sample and incubated
at 37 °C for 1 h. Blue loading buﬀer 6× (New England Biolabs) was
added to samples and 20 μL added to a 0.7% agarose gel in 0.5× TBE
buﬀer. DNA was visualized with SYBR gold (Invitrogen) and a
Typhoon FLA9000 Scanner (GE Healthcare).
Determination of IC50. The in vitro assay was run as described
above with 1b, 3b, and 9b at concentrations titrated at 10-fold and 3-
fold intervals ranging from 10 nM to 33 μM, 330 pM to 10 μM, and 33
pM to 1 μM, respectively, and DNA at 50 pM. The substrate DNA
fragment (7.5 kb) was PCR ampliﬁed from PTYB21 (New England
Biolabs) after linearization with BamHI (New England Biolabs).
Primers 5′-ACTTTTCGGGGAAATGTGCG-3′ and 5′-TTAG-
AGGCCCCAAGGGGTTA-3′ (IDT DNA) were used for ampliﬁca-
tion with the Expand Long Template PCR System (Roche). The
amplicon was isolated with QIAquick PCR Puriﬁcation Kit (Qiagen),
and the amplicon size was veriﬁed by agarose gel electrophoresis. After
the ethanol precipitation step which follows methylation, the DNA
pellet was dissolved in 100 μL of 2% SDS and incubated overnight at
55 °C to wash oﬀ residual polyamide. The high aﬃnity of 9b made this
additional wash step necessary prior to MluI digestion. To the
solution, 10 μL of 2 M NaCl followed by 2.5 volumes of ethanol were
added to reprecipitate the DNA. The pellet was washed twice with
cold 75% ethanol before submission to MluI digest, as described
above. Digested samples were run on 1% agarose gels and visualized
with SYBR Gold. Gels were scanned on a Typhoon FLA Scanner (GE
Healthcare) and the bands quantitated using ImageQuant Software
(GE Healthcare). Percentage inhibition was normalized against
maximal methylation in the presence of no inhibitor.
= × −⎜ ⎟⎛⎝
⎞
⎠%Inhibition 100% 1
% uncut DNA
% maximal uncut DNA
IC50 curves and 95% conﬁdence intervals were determined using
GraphPad Prism by variable-slope, nonlinear regression ﬁt to a dose
response model with a bottom constraint of 0. At least three replicates
of each concentration were used.
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